Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04364048
Title Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Rachel Sanborn
Indications

lung non-small cell carcinoma

Therapies

Pemetrexed Disodium

Durvalumab

Paclitaxel

Etoposide

Docetaxel

Carboplatin

Cisplatin

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.